Circulate Health Raises $12 Million in Seed Funding to Accelerate Research in Longevity and Expand Therapeutic Plasma Exchange (TPE) Treatment Centers

Led by Khosla Ventures, the financing follows the release of Circulate's trial study, the first of its kind to demonstrate the effectiveness of TPE in improving healthspan and reducing biological age

NOVATO, Calif., July 2, 2025 /PRNewswire/ -- Circulate Health, a longevity startup dedicated to harnessing the potential of therapeutic plasma exchange (TPE) to advance human healthspan and lifespan, announced today that it raised $12 million in a seed funding led by Khosla Ventures, with participation from Seaside Ventures and CSC Ventures.

A patented method of therapeutic plasma exchange uses a procedure that separates, removes, and replaces a patient's plasma to treat inflammation, improve healthspan, and address certain chronic diseases. Circulate has been operating in stealth for the past three years, studying the benefits of TPE and its ability to improve human healthspan and address the hallmarks of again, while partnering with clinics to deliver TPE across the country and soon internationally.

Circulate was founded based on scientific research from world-renowned geroscientist Eric Verdin, MD, who is a co-founder of Circulate and CEO of the Buck Institute of Research on Aging. In partnership with the Buck Institute and led by scientific advisor David Furman PhD, Circulate recently published a clinical trial that found TPE combined with intravenous immunoglobin (IVIG) reduced patients' biological age by an average of 2.6 years, as measured by multi-omics biomarkers.

"We have been immensely dedicated to our research and delivering the highest quality medical care to patients and clinic partners in order to further address healthspan, and the hallmarks of aging," said Brad Younggren, MD, CEO and co-founder of Circulate. "Khosla Ventures' investment into our work truly demonstrates the power of and potential for the work we're doing. We plan to use these additional funds to expand our clinic network across the country and internationally, and provide greater access to those seeking access to a therapy shown to improve biomarkers and biological clocks."

"We incubated Circulate to explore whether a safe, well-understood therapy like TPE could counter the deleterious effects of aging, and offer broader health benefits like potentially removing microplastics from the body," said Alex Morgan of Khosla Ventures. "Early clinical results are promising, and we're excited to continue backing the team as they work to make TPE more accessible to more people."

Circulate scientific advisory board also includes Matt Kaeberlein PhD and Alex Aravanis MD PhD, both providing additional expertise and strategic guidance.

Circulate Health already has 24 partner clinics, across 8 states, and the Circulate Network is expected to grow to over 50 clinics by the end of 2025 in the U.S. and abroad.

Clinicians and patients can learn more about Circulate at www.circulate.health.

About Circulate Health
Circulate Health is pioneering technologies to improve healthspan and reduce biological age.

SOURCE Circulate Health